Merck (NYSE:MRK) is reportedly in advanced talks to buy immuno-oncology company Harpoon Therapeutics (NASDAQ:HARP) for around $700M. Citing people familiar…
Read More »Merck (NYSE:MRK) is reportedly in advanced talks to buy immuno-oncology company Harpoon Therapeutics (NASDAQ:HARP) for around $700M. Citing people familiar…
Read More »